|
Evaluation and Follow-up of Patients with Cryptococcosis Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Evaluation and Follow-up of Patients with Cryptococcosis conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Evaluation and Follow-up of Patients with Cryptococcosis Clinical research trials and Evaluation and Follow-up of Patients with Cryptococcosis health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Evaluation and Follow-up of Patients with Cryptococcosis. Evaluation and Follow-up of Patients with Cryptococcosis Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Evaluation and Follow-up of Patients with Cryptococcosis clinical trial. Participants oftentimes recieve the most expert healthcare available for their Evaluation and Follow-up of Patients with Cryptococcosis condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Evaluation and Follow-up of Patients with Cryptococcosis  Evaluation and Follow-up of Patients with Cryptococcosis
Evaluation and Follow-up of Patients with Cryptococcosis
For Condition: Cryptococcosis,Lymphopenia
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: This 5-year study will follow the course of disease in previously healthy patients with cryptococcosis who developed the disease for no identifiable reason. Individuals with a positive culture of Cryptococcus neoformans 18 years of age and older without HIV infection or other condition predisposing to cryptococcosis (such as high-dose corticosteroid therapy, sarcoidosis, or a blood cancer) may be eligible for this study. Candidates who test positive for HIV infection may not participate. Participants will have a physical examination, medical history, routine blood tests and assessment of disease activity upon entering the study. Patients who may have active cryptococcosis will also have a lumbar puncture (spinal tap) and additional blood tests. Following the initial evaluation, patients receiving treatment for cryptococcosis will come to the NIH Clinical Center as needed to manage their disease, typically no less than every 3 months. Other patients will be seen every 6 to 12 months. The visits will include a medical history, physical examination, and blood and urine tests.
Details: Cryptococcosis is a fungus which causes infection in immunocompromised patients, such as those with the acquired immunodeficiency syndrome, but also in occasional persons who have been previously healthy. The reasons for infection of ostensibly normal persons remain unclear. Nowthat enumeration of lymphocyte subpopulations has become more common, a low number of DC4 cells have been found in some cryptococcosis patients. These patients fit the CDC definition of 1diopathic CD4 Lmphocytopenia (ICL) in that they have CD4 levels below 300/ul, no laboratory evidence of HIV infection and no defined immunodeficiency or therapy associated with depressed CD4 levels (MMWR, July 31, 1992). One of the first five cases of ICL reported in that issue of MMWR was presented with cryptococcal meningitis. According to Dr. Harold Jaffe at CDC, about one fourth of the ICL cases reported to CDC by December, 1992 have presented with cryptococcosis (personal communication.) However the incidence of ICL in cryptococcosis patients is unknown. Also, the long term outcome of patients with cryptococcosis and ICL patients is unclear. For example, it is not known if they are more difficult to cure than other previously normal patients, as would be the case had they been HIV seropositive. This protocol will bring cryptococcosis patients to NIH who have no underlying disease, either with or without prior treatment of their mycosis. Those who have ICL will be compared with those not having ICL for response to treatment, prior and future opportunistic infections other than cryptococcosis, and future course of the lymphocyte subpopulations.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Positive culture of Cryptococcus neoformans from any body site; Age 18 years or older; and Ability to provide informed consent. EXCLUSION CRITERIA: Known HIV positive serology or other condition predisposing to Cryptococcosis, including but not limited to corticosteroid therapy equivalent to prednisone 20 mg per day or more, acidosis or hematologic malignancy. Dementia impairing informed consent.
Total Enrollment: 50
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 930106; 93-I-0106
Study Start Date: March 10, 1993
Record last reviewed: April 2, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001352
Other Cryptococcosis Studies:
1. Evaluation and Follow-up of Patients with Cryptococcosis
2. Evaluation of the Association of Polymorphisms in the Innate Immune System with the Risk for Cryptococcus neoformans Infection in Patients not Infected with HIV and Complications Associated with Cryptococcus neoformans Infection
Related Studies:
Other Cryptococcosis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Evaluation and Follow-up of Patients with Cryptococcosis
|
|
|
|
|
|
|
|
